- Pro forma net sales growth of 3% to $87 million
- Adjusted (Non-GAAP) Net Income of $0.10 per share; GAAP Net Income of $0.06 per share
- Adjusted EBITDA of $13.8 million; or $0.39 per share, a 26% YOY increase
- Operating cash flow of $11.1 million
Trade-Ideas LLC identified AngioDynamics (ANGO) as a strong on high relative volume candidate
AngioDynamics (ANGO) shares are falling after the company reported weaker-than-expected third quarter earnings and revenue results.
AngioDynamics (ANGO) shares are rising after the company beat analysts' second quarter earnings and revenue expectations.